Epinephrine Market size was over USD 1.25 billion in 2024 and is likely to exceed USD 5.77 billion by the end of 2037, witnessing over 12.3% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of epinephrine is evaluated at USD 1.37 billion.
The growth of the market can be attributed to the worldwide growing prevalence of several allergic reactions, along with the surge in neurological disorders. It is observed that every year, around 6 million people worldwide die from neurological disorders. In addition to this, the rising proportion of individuals who are prone to several allergies is another major factor that is estimated to boost the market growth throughout the forecast period.
In addition to these, factors that are believed to fuel the market growth of epinephrine include the upsurge in food allergy stances throughout the world. For instance, in the United States, approximately 33 million individuals are affected by food allergies. Furthermore, epinephrine is used as the first line of treatment to help reverse the effects of anaphylaxis. Individuals suffering from anaphylactic shock frequently use auto-injectors, as they are easy administer by non-medical personnel. Therefore, the rising occurrence of anaphylaxis cases is another significant factor that is estimated to fuel the growth of the market over the forecast period. For instance, anaphylaxis, a severe allergic reaction to food, is thought to cause nearly 91,000 emergency room visits annually in the United States.
Growth Drivers
Upsurge in Chronic Respiratory Disorders - Respiratory disorders refer to a class of pathogenic conditions such as COPD, and asthma, that affect respiration in living organisms. In higher organisms, respiration allows for gas exchange. In a gas exchange, the organism absorbs oxygen and exhales carbon dioxide. The respiratory tract, which comprises the alveoli, bronchi, bronchioles, pleura, pleural cavity, trachea, and breathing muscles and nerves, is where respiratory disease develops itself. Therefore, the global increase in chronic respiratory disorders is expected to boost the growth of the global epinephrine market. As per the World Health Organization (WHO), 3.23 million people died from chronic obstructive pulmonary disease (COPD), the third most common cause of mortality in the world in 2019.
Growing Occurrence of Several Types of Allergic Reactions - For instance, every year, more than 51 million individuals in the United States deal with various allergies. These allergic reactions are the region's sixth most common cause of chronic illness.
Escalation in Cardiac Arrests - It is observed that, in the United States, there are over 357,000 out-of-hospital cardiac arrests (OHCA) each year, with nearly 89% of them life-threatening.
Increasing Development in Auto-Injectors - For instance, until now, nearly 81 auto-injectors have been developed by more than 22 drug manufacturers across the globe. For use with auto-injectors, about 49 medicines are created as combination products. Out of these, disposable auto-injectors make up nearly 61% of the total. Reusable auto injectors with various doses are being developed at a remarkable rate.
Increasing Healthcare Expenditure - As per the World Bank data, in 2019, global healthcare expenditures expanded by 9.83%.
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
12.3% |
|
Base Year Market Size (2024) |
USD 1.25 billion |
|
Forecast Year Market Size (2037) |
USD 5.77 billion |
|
Regional Scope |
|
Application (Cardiac Arrest, Anaphylaxis, Superficial Bleeding, Respiratory Disorders)
The global epinephrine market is segmented and analyzed for demand and supply by application into cardiac arrest, anaphylaxis, superficial bleeding, respiratory disorders, and others. Out of these five types of segments, the anaphylaxis segment is anticipated to hold the highest share over the forecast period. The growth of the segment can be attributed to the rising development of technologically advanced products from the key players, and the globally increasing prevalence of anaphylaxis in pediatrics as well as in adults. For instance, in a clinical study, it was observed that the prevalence of anaphylaxis in children ranges from 1 to 762 per 100,000 person-years. This prevalence rate varied throughout continents; such, in Europe it ranged from 2.4 to 762 per 100,000 person-years, whereas it ranges between 0.8 to 72 per 100,000 person-years in North America. Moreover, the anaphylaxis incidence rate in the pediatric population ranges from 0.05% to 1.7% throughout the world.
Type (Prefilled Syringes, Auto-Injectors, Ampoules & Vials)
The global epinephrine market is also segmented and analyzed for demand and supply by type into epinephrine prefilled syringes, epinephrine auto-injectors, ampoules & vials, and others. Amongst these segments, the epinephrine auto-injectors segment is expected to garner a significant share. The growth of the segment can be attributed to their easy availability, easy to use, and great efficiency in treating acute anaphylaxis. On the other hand, the prefilled syringes segment is projected to witness notable growth during the forecast period, owing to its surging demand in hospitals and clinics for treating several illnesses, coupled with its rapid responsive rate in the treatment of emergency allergic reactions.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Application |
|
|
By Distribution Channel |
|
North American Market Forecast
The North America epinephrine market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. The growth of the market can be attributed majorly to the escalating count of patients suffering from respiratory diseases such as asthma, coupled with the rapidly expanding population in the region. According to a health survey conducted between 2018 - 2020, in the United States, the surge of asthma cases in young individuals aged 18+ years reached 21,030,480 which denotes nearly 8.3% growth. Further, the rising awareness about allergies, along with the growing prevalence of cardiac arrests among people is another significant factor that is anticipated to push the market growth further throughout the forecast period in the region.
Europe Market Forecast
Further, the Europe epinephrine market is projected to display notable growth over the forecast period on the back of the escalating prevalence of cardiovascular disorders, along with a surging ratio of anaphylaxis in the region. For instance, in Europe, cardiovascular disorders continue to be the main cause of death, contributing to almost 47% of all mortalities. Every year, more than 5 million people die from cardiovascular disorders in the European region. Additionally, the surge in technological advanced products is another major factor that is projected to spur the epinephrine market size over the projected time frame in the region.
Pfizer Inc. announced that it is in coordination with FDA to extend the expiration dates of certain lots of EpiPen 0.3 mg Auto-Injectors after reviewing the stability data. Pfizer works to stabilize the supply of these particular lots of products so that patients feel confident using them.
Teva Pharmaceuticals Industries Ltd. announced the accessibility of the FDA-approved generic version of EpiPen Jr 1 (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the U.S. Currently, the product is available in pharmacies nationwide.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?